Profile
AQST ZTS TAK HLN TEVA ITCI
Company Name Aquestive Therapeutics, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $298.59M $73.21B $48.16B $45.90B $17.02B $14.00B
Employees 0.14K 13.80K 49.28K 24.56K 33.89K 0.86K
CEO Mr. Daniel Barber Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Sharon Mates Ph.D.
Ratings
AQST ZTS TAK HLN TEVA ITCI
Quant Rating Score 2 3 3 3 1 1
Quant Rating Sell Neutral Neutral Neutral Strong Sell Strong Sell
Trading
AQST ZTS TAK HLN TEVA ITCI
Last Close $2.87 $159.61 $15.19 $10.45 $14.85 $131.87
High 52 $5.66 $196.48 $15.19 $10.69 $22.77 $131.91
Low 52 $2.31 $145.54 $12.6 $8.01 $12.78 $64.76
Price vs. 52 Week High -49.29 % -18.77 % 0 % -2.25 % -34.78 % -0.03 %
Price vs. 52 Week Low 24.24 % 9.67 % 20.56 % 30.46 % 16.2 % 103.63 %
Total Return
AQST ZTS TAK HLN TEVA ITCI
1 Month Return 5.13 % -6.06 % 2.29 % -2.06 % -5.35 % 0.48 %
3 Month Return -19.83 % -2.27 % 14.56 % 10.47 % -30.08 % 57.51 %
6 Month Return -42.02 % -16.01 % 5.27 % 0.77 % -15.09 % 80.92 %
9 Month Return 19.09 % -9.52 % 16.18 % 23.52 % -11.32 % 90.92 %
YTD Return -19.38 % -2.04 % 14.73 % 9.54 % -32.62 % 57.89 %
1 Year Return -31.01 % -3.57 % 12.69 % 26.97 % 6.6 % 96.21 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AQST ZTS TAK HLN TEVA ITCI
Dividend Yield Percentage (TTM) - 1.1 % 4.23 % 0.01 % - -
Dividend Paid and Capex Coverage Ration (TTM) -224.9 % 2.05 % 1.76 % - 2.5 % -227.26 %
Dividend Per Share (TTM) - 1.8 % 192 % 0.02 % - -
Payout Ratio (TTM) - 31.62 % 145.09 % - - -
Growth
AQST ZTS TAK HLN TEVA ITCI
Asset Growth 76.64 % -0.34 % 8.25 % 0.76 % -9.55 %
Gross Profit Growth 33.4 % 12.05 % 1.76 % -0.19 % 5.47 %
Revenue Growth 13.8 % 8.33 % 5.87 % -0.61 % 4.4 %
Revenue 3 Year -50.28 % 24.31 % 33.13 % 18.32 % 1.52 %
Revenue 5 Year -68.01 % 55.65 % 103.83 % 33.18 % -5.5 %
Revenue 10 Year -68.6 % 113.39 % 152.69 % 33.18 % -38.45 %
EBIT Growth -103.75 % 103.71 % -56.36 % 10.52 % -169.98 %
Net Income Growth -460.83 % 6.06 % -54.56 % 37.46 % -193.2 %
Net Income 3 Yeari Growth Per Share 78.48 % 27.46 % -61.74 % 4.3 % -482.97 %
Net Income 5 Yeari Growth Per Share 82.24 % 74.46 % 32.36 % 121.35 % -58.26 %
Net Income 10 Yeari Growth Per Share -29.85 % 370.4 % 35.42 % 121.35 % -140.46 %
Operating Income Growth -103.75 % 103.71 % -56.36 % 10.52 % -169.98 %
Operating Cash Flow Growth (CFG) -460.49 % 25.5 % -26.69 % 9.57 % -8.85 %
Operating 3 Year CFG 52.39 % 39.36 % -29.25 % 70.61 % 52.26 %
Operating 5 Year CFG 82.64 % 73.18 % 118.64 % 194.34 % 123.59 %
Operating 10 Year CFG -23.57 % 420.39 % 384.17 % 194.34 % -81.66 %
EPS Growth -292.31 % 7.68 % -54.92 % 45.45 % -190 %
EPS Diluted Growth -292.31 % 7.89 % -54.86 % 45.45 % -190 %
Book Value Per Share 60.1 % -2.96 % 13.54 % -2.19 % -30.36 %
Share Holder 3 Year Equity Growth Per Share 67.84 % 9.65 % 40.38 % -38.33 % -49 %
Share Holder 5 Year Equity Growth Per Share -187.29 % 85.42 % 41.33 % -40.51 % -62.86 %
Share Holder 10 Year Equity Growth Per Share 3.31 % 301.38 % 195.14 % -40.51 % -82.6 %
Dividend Per Share Growth - 15.33 % 1.95 % 48.16 % -
Dividend 3 Year Growth Per Share - 73.18 % 1.19 % -50.08 % -
Dividend 5 Year Growth Per Share - 163.51 % 101.42 % -50.25 % -100 %
Dividend 10 Year Growth Per Share - 493.89 % 102.58 % -50.25 % -100 %
Debt Growth 14.06 % -0.16 % 10.53 % 8.79 % -10.29 %
Free Cash Flow Growth -387.02 % 41.76 % -31.4 % 16.27 % -11.05 %
Updated On 31 Dec 2024 31 Dec 2024 31 Mar 2024 31 Dec 2024 31 Dec 2024
Profitability
AQST ZTS TAK HLN TEVA ITCI
Gross Profit Margin TTM 68.95 % 69.85 % 54.74 % 61.52 % 48.74 % 91.63 %
Return on Assets TTM -43.52 % 17.46 % 1.38 % 4.2 % -4.17 % -5.46 %
Return on Equity TTM 99.54 % 49.65 % 2.83 % 8.73 % -26.15 % -7.4 %
Return on Capital Employed TTM -37.27 % 24.27 % 3.62 % 7.74 % -1.14 % -10.05 %
Net Income Per EBT TTM 99.97 % 79.35 % 89.75 % 75.5 % 127.75 % 100.64 %
EBT Per Ebit TTM 143.48 % 119.26 % 49.18 % 86.58 % 423.43 % 63.57 %
EBIT Per Revenue TTM -53.46 % 28.38 % 10.3 % 19.64 % -1.83 % -17.15 %
Cash Flow To Debt Ratio TTM -94.09 % 43.79 % 22.2 % - 6.9 % -430.93 %
Receivables Turnover TTM 7.84 7.03 6.23 - 5.41 4.09
Payables Turnover TTM 1.74 6.45 4.5 2.19 3.85 2.18
Inventory Turnover TTM 2.96 1.21 1.66 3.63 2.82 2.17
Fixed Asset Turnover TTM 640.92 % 256.4 % 226.93 % 584.75 % 334.34 % 4569.25 %
Asset Turnover TTM 56.75 % 65.01 % 30.31 % 32.73 % 42.07 % 49.79 %
Operating Cash Flow Per Share TTM -0.39 6.5 678.77 - 1.1 -0.71
Free Cash Flow Per Share TTM -0.39 5.06 484.07 - 0.66 -0.71
Cash Per Share TTM 78.45 % 437.03 % 33271.95 % 24.05 % 291.26 % 970.67 %
Operating Cash Flow Sales Ratio TTM -62.12 % 31.9 % 23.47 % - 7.54 % -10.75 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.44 % 77.82 % 71.32 % - 60.06 % 100.44 %
Cash Flow Coverage Ratios TTM -94.09 % 43.79 % 22.2 % - 6.9 % -430.93 %
Price To Free Cash Flows Ratio TTM -8.31 31.86 9.39 - 22.99 -190.53
Price To Operating Cash Flows Ratio TTM -7.7 25.15 6.69 - 13.65 -185.61
Price Cash Flow Ratio TTM -7.7 25.15 6.69 - 13.65 -185.61
Income Statement (TTM)
AQST ZTS TAK HLN TEVA ITCI
Revenue $0.06B $9.26B $4263.76B $11.23B $16.54B $0.68B
Gross Profit $0.04B $6.54B $2832.26B $6.95B $8.06B $0.62B
Gross Profit Ratio 68.95% 70.62% 66.4% 61.85% 48.74% 91.63%
EBITDA $-0.03B $3.86B $874.6B $2.51B $-0.3B $-0.12B
Net Income $-0.04B $2.49B $144.07B $1.44B $-1.64B $-0.07B
EPS Diluted -0.51 5.47 91.16 0.16 -1.45 -0.72
Balance Sheet (MRQ)
AQST ZTS TAK HLN TEVA ITCI
Long Term Debt $0.04B $5.39B $5029.93B $8.71B $16.3B $0.01B
Total Liabilities $0.16B $9.47B $7834.79B $18.09B $33.61B $0.22B
Total Equity $-0.06B $4.77B $7274.01B $16.22B $5.72B $1.15B
Total Investments $0B $0B $445.7B $0.08B $0B $0.69B
Total Debt $0.04B $6.74B $4843.75B $10.29B $18.08B $0.02B
Total Assets $0.1B $14.24B $15108.79B $34.32B $39.33B $1.37B
Cash Flow Statement (TTM)
AQST ZTS TAK HLN TEVA ITCI
Net Income $-0.04B $2.5B $144.07B $1.44B $-1.96B $-0.07B
Inventory $0B $-0.04B $-115.74B $0.22B $0.17B $-0.01B
Dividends Paid $0B $-0.79B $-287.19B $-0.57B $0B $0B
Operating Cash Flow $-0.04B $2.95B $716.34B $2.3B $1.25B $-0.07B
Capital Expenditure $-0B $-0.66B $-480.73B $-0.25B $-0.5B $-0B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.29
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.33
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 9.27
ALVOW Alvotech 1.36
AMPH Amphastar Pharmaceuticals, Inc. 27.24
AMRX Amneal Pharmaceuticals, Inc. 7.81
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 68.29
ASRT Assertio Holdings, Inc. 0.683
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 7.2
AYTU Aytu BioPharma, Inc. 1.07
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to AQST
Unlock